Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_24948 details
Primary information
SALIDSAL_24948
Biomarker namehsa-miR-3190-3p
Biomarker TypeDiagnostic
Sampling MethodSaliva samples were collected from consecutive patients with a diagnosis of primary OSCC
Collection MethodUnstimulated whole saliva was collected after mouth rinsing with 10 mL of sterile PBS and immediately processed by centrifugation
Analysis MethodqRT-PCR
Collection SiteSaliva
Disease CategoryCancer
Disease/ConditionOral Cancer
Disease SubtypeOral squamous cell carcinoma (OSCC)
Fold Change/ Concentration0.888
Up/DownregulatedUpregulated
ExosomalNA
OrganismHomo sapiens
PMID33456584
Year of Publication2021
Biomarker IDhsa-miR-3190-3p
Biomarker CategorymiRNA
SequenceUGUGGAAGGUAGACGGCCAGAGA
Title of studyGenome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma
Abstract of studySurvival rates of oral squamous cell carcinoma (OSCC) remained substantially unchanged over the last decades; thus, additional prognostic tools are strongly needed. Salivary miRNAs have emerged as excellent non-invasive cancer biomarker candidates, but their association with OSCC prognosis has not been investigated yet. In this study, we analyzed global salivary miRNA expression in OSCC patients and healthy controls, with the aim to define its diagnostic and prognostic potential. Methods: Saliva was collected from patients with newly diagnosed untreated primary OSCC and healthy controls. Global profiling of salivary miRNAs was carried out through a microarray approach, while signature validation was performed by quantitative real-time PCR (RT-qPCR). A stringent statistical approach for microarray and RT-qPCR data normalization was applied. The diagnostic performance of miRNAs and their correlation with OSCC prognosis were comprehensively analyzed. Results: In total, 25 miRNAs emerged as differentially expressed between OSCC patients and healthy controls and, among them, seven were significantly associated with disease-free survival (DFS). miR-106b-5p, miR-423-5p and miR-193b-3p were expressed at high levels in saliva of OSCC patients and their combination displays the best diagnostic performance (ROC - AUC = 0.98). Moreover, high expression of miR-423-5p was an independent predictor of poor DFS, when included in multivariate survival analysis with the number of positive lymph nodes - the only significant clinical prognosticator. Finally, we observed a significant decrease in miR-423-5p expression in matched post-operative saliva samples, suggesting its potential cancer-specific origin. Conclusion: Salivary miRNAs identified in our cohort of patients show to be accurate in OSCC detection and to effectively stratify patients according to their likelihood of relapse. These results, if validated in an independent set of patients, could be particularly promising for screening/follow-up of high-risk populations and useful for preoperative prognostic assessment.